Given the established link between constant B cell receptor (BCR) activation, mediated by BTK, and CLL pathogenesis, the hypothesis regarding the detrimental impact of BTK inhibition on lymphoma cell survival gained traction. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.